Table 1 Demographic data and prevalence rates of Pneumocystis jirovecii pneumonia (formerly known as Pneumocystis carinii pneumonia (PcP)) and CMV infection in HIV-uninfected non-Hodgkin lymphoma patients.
From: Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
Rituximab group N = 7554 (100%) | Control group N = 4604 (100%) | p value | |
|---|---|---|---|
Age (y) | 61.0 ± 16.0 | 49.5 ± 21.5 | <0.0001 |
Gender ratio | <0.0001 | ||
Male | 4138 (54.7%) | 2808 (60.9%) | |
Female | 3416 (45.2%) | 1796 (39.0%) | |
Chronic pulmonary disease | 2624 (34.7%) | 1474 (32.0%) | <0.001 |
Rheumatologic diseases | 1849 (24.4%) | 794 (17.2%) | <0.0001 |
Diabetes mellitus (DM) | 1694 (22.4%) | 717 (15.5%) | <0.0001 |
DM with chronic complications | 455 (6.0%) | 174 (3.7%) | <0.0001 |
Chronic kidney disease | 1849 (24.4%) | 794 (17.2%) | <0.0001 |
Pneumocystis jirovecii pneumonia (PcP) | 223 (2.95%) | 61 (1.32%) | <0.0001 |
Cytomegalovirus (CMV) | 75 (0.99%) | 45 (0.98%) | 0.93 |
